Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714484 | 1.00 | RAB9A (0.55) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL29631623 | 0.82 | PAX8 (0.65) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL5051613 | 0.82 | PAX8 (0.65) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL8342118 | 0.82 | PAX8 (0.65) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL9735520 | 0.82 | RAB9A (0.58) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL28643368 | 0.82 | RAB9A (0.58) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL28952987 | 0.80 | PAX8 (0.70) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL5096307 | 0.79 | RAB9A (0.60) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL2682159 | 0.77 | PAX8 (0.67) | RAB9ASMN1; SMN2LMNANPC1MEN1 | |
| SCHEMBL12720910 | 0.77 | RAB9A (0.58) | RAB9ASMN1; SMN2LMNAL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053977-A1 | Medicinal uses of hydrazones | ALMSTEAD JI-IN KIM (US) | 2004-03-18 | — | — | US | claimed |
| US-6660737-B2 | Antihypoxic agents | THE PROCTER & GAMBLE COMPANY | 2003-12-09 | — | — | US | claimed |
| US-20030092716-A1 | Medicinal uses of hydrazones | THE PROCTER & GAMBLE COMPANY | 2003-05-15 | — | — | US | claimed |
| EP-0313630-A1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. | DEUTSCHES AUSSATZIGEN HILFSWER (DE) | 1989-05-03 | — | — | EP | claimed |
| WO-1988008842-A2 | SUBSTITUTED 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME | DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) | 1988-11-17 | — | — | WO | claimed |
| US-20040053977-A1 | Medicinal uses of hydrazones | ALMSTEAD JI-IN KIM (US) | 2004-03-18 | — | — | US | disclosed |
| US-6660737-B2 | Antihypoxic agents | THE PROCTER & GAMBLE COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030092716-A1 | Medicinal uses of hydrazones | THE PROCTER & GAMBLE COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-0313630-A1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. | DEUTSCHES AUSSATZIGEN HILFSWER (DE) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053977-A1 | Medicinal uses of hydrazones | PGF, VEGFA, TEK | RAB9A 3979/4885SMN1; SMN2 2892/4885LMNA 3481/4885 |
| US-20030092716-A1 | Medicinal uses of hydrazones | EPOR, VEGFA, HIF1A | RAB9A 3507/4885SMN1; SMN2 2163/4885LMNA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.